계명대학교 의학도서관 Repository

Determinants of clinical outcomes of gastric cancer patients treated with neoadjuvant chemotherapy: a sub-analysis of the PRODIGY study

Metadata Downloads
Author(s)
Hyung-Don KimJong Seok LeeYoung Soo ParkJeong Hwan YookSung Hoon NohYoung-Kyu ParkYoung-Woo KimSang Cheul OhJong Gwang KimMin-Hee RyuJae-Ho CheongHyunKi KimJoon Seok LimJae-Hyuk LeeSuk Hee HeoJin Young KimMi Hwa HeoYoung Iee ParkIn-Ho KimYoon-Koo Kang
Keimyung Author(s)
Heo, Mi Hwa
Department
Dept. of Internal Medicine (내과학)
Journal Title
Gastric Cancer
Issued Date
2022
Volume
25
Issue
6
Keyword
Clinical stageGastric cancerNeoadjuvant chemotherapyPost-neoadjuvant chemotherapy pathological stage
Abstract
Background:
In this post hoc analysis of the PRODIGY study, we aimed to investigate factors associated with survival outcomes and provide evidence for designing optimal perioperative treatment strategies for gastric cancer patients receiving neoadjuvant chemotherapy.

Patients and methods:
A total of 212 patients in the neoadjuvant chemotherapy group of the PRODIGY study were included as the study population. The prognostic impact of clinicopathologic factors, including the initial radiological clinical stage (cStage) and post-neoadjuvant chemotherapy pathological stage (ypStage), was analyzed.

Results:
The median age was 58 years. The majority of patients (77.4%) had cStage III disease, and about 10% and 25% had ypStage 0 and I disease, respectively. According to the initial cStage, progression-free survival (PFS) and overall survival (OS) were significantly different (P < 0.01). PFS and OS were also different according to the ypStage (P < 0.01). In multivariate analyses, cStage IIIC disease (vs. cStage II) and ypStage II and III disease (vs. ypStage 0/I) were independent factors for poor survival outcomes. Based on the patterns of PFS and OS according to both cStage and ypStage, three patient groups were defined. These groups showed distinct PFS and OS (P < 0.01) with 5-year PFS rates of 95.7%, 77.9%, and 31.3% and 5-year OS rates of 95.7%, 82.4%, and 42.5%, respectively.

Conclusions:
Both initial cStage and ypStage were independent factors for survival outcomes of gastric cancer patients treated with neoadjuvant chemotherapy. Efforts should be made to develop optimal peri-operative treatment strategies for patients at different risks according to cStage and ypStage.
Keimyung Author(s)(Kor)
허미화
Publisher
School of Medicine (의과대학)
Type
Article
ISSN
1436-3305
Source
https://link.springer.com/article/10.1007/s10120-022-01325-6
DOI
10.1007/s10120-022-01325-6
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/44534
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록
  • 관련 파일이 존재하지 않습니다.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.